Imaging With a PET Agent for Detection of Cancers of the Head and Neck

Description

The purpose of this study is to test the safety of a study drug called PARPi-FL. This drug has been tested in animals but not yet in people. The purpose of this study is to test if a PARPi-FL scan can be used to take pictures of head and neck cancer. The usual approach to imaging this cancer includes several different imaging scans, including x-rays, CT (computed tomography), MRI (magnetic resonance imaging), and PET (positron emission tomography). These tests take pictures of the cancer.

Conditions

Head and Neck Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to test the safety of a study drug called PARPi-FL. This drug has been tested in animals but not yet in people. The purpose of this study is to test if a PARPi-FL scan can be used to take pictures of head and neck cancer. The usual approach to imaging this cancer includes several different imaging scans, including x-rays, CT (computed tomography), MRI (magnetic resonance imaging), and PET (positron emission tomography). These tests take pictures of the cancer.

Safety, Biodistribution and Radiation Dosimetry of [18F]PARPi

Imaging With a PET Agent for Detection of Cancers of the Head and Neck

Condition
Head and Neck Cancer
Intervention / Treatment

-

Contacts and Locations

New York

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥18 years
  • * ECOG performance status 0 or 1
  • * Biopsy (histologically or cytologically) proven Squamos Cell Carcinoma
  • * Oral cavity, oropharynx, or nasopharynx primary site
  • * At least one tumor lesion on standard of care imaging with a minimum diameter of at least 1.5 cm
  • * Scheduled to undergo treatment at MSKCC
  • * Willingness to sign informed consent
  • * Age ≥18 years
  • * ECOG performance status 0 or 1
  • * Biopsy (histologically or cytologically) proven Squamous Cell Carcinoma
  • * Oral cavity,oropharynx, or nasopharynx primary site
  • * Scheduled to undergo surgery (neck dissection and/ or neck dissection + surgical removal of the primary) at MSK
  • * Willingness to sign informed consent
  • * Should have had a standard-of-care \[18F\]-FDG PET/CT scan before surgery (to minimize the possibility of new alterations developing between the two scans both scans should be acquired within a maximum time difference of one month).
  • * Significantly impaired organ function that may interfere with the excretion and metabolism of the imaging agent. Specifically, patients will be excluded if they meet the following criteria:
  • * Hematologic
  • * Hepatic
  • * Bilirubin \>2.0 x ULN (institutional upper limits of normal)
  • * AST/ALT \>2.5 x ULN
  • * Renal
  • * Claustrophobia interfering with PET/CT imaging
  • * Known allergy to PEG300
  • * Pregnancy or breastfeeding

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Heiko Schöder, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2025-08